United States · 
What does Bay City Capital invest in?
Bay City Capital invests most often at Series A and Series B (52% of the rounds on record), in sectors such as Life Sciences.
Bay City Capital highlights
- 01
76 rounds on record
- 02
Mostly Series A and Series B: 52% of its rounds
- 03
Sole investor in 12 rounds, median $10M
- 04
20 exits from the portfolio
What they do
5 venture capital funds $1.3 billion in capital commitments Invested in over 100 companies worldwideFrom their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Life Sciences
- Based in
- Dallas, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first76 appearances
- 2017
5 rounds
- Jul
- Jul
- Jun
- May
- Jan
- 2016
1 round
- Jul
- 2015
1 round
- Apr
- 2014
6 rounds
- Dec
- Sept
- Aug
- Aug
- Jan
- Jan
- 2013
10 rounds
- Oct
- Oct
- Oct
- Sept
- Jul
- Jun
- May
- Mar
- Mar
- Feb
- 2012
3 rounds
- Nov
- Apr
- Feb
- 2011
6 rounds
- Dec
- Oct
- Jul
- Jun
- Feb
- Jan
- 2010
6 rounds
- Nov
- Oct
- Apr
- Mar
- Jan
- Jan
- 2009
8 rounds
- Nov
- Nov
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration1 named
CGCarl Goldfischer, MDManaging Director of the Managing MemberiFiling they signed
We also hold 9 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
0 of 1 we have independently watched raise
Browsehappy
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed20 in all
Hyperion TherapeuticsBought by Horizon Pharma$1.1BMar 2015
Civitas TherapeuticsBought by Acorda Therapeutics$525MSept 2014
Aciex TherapeuticsBought by NicOx$120MJul 2014
Cadence PharmaceuticalsBought by Mallinckrodt$1.3BFeb 2014
NuPatheBought by Endo Health Solutions$105MDec 2013
IDEV TechnologiesBought by Abbott Labs$310MJul 2013
PTC TherapeuticsListed$125MJun 2013
Conatus PharmaceuticalsListed$69MJun 2013
EpizymeListed$60MMay 2013
MAP PharmaceuticalsBought by Allergan$958MJan 2013
EpocratesBought by AthenahealthUndisclosedJan 2013
NextWave PharmaceuticalsBought by PfizerUndisclosedOct 2012
Aragon SurgicalBought by AesculapUndisclosedSept 2011
Calypso MedicalBought by Varian Medical SystemsUndisclosedSept 2011
EpocratesListedUndisclosedFeb 2011
Ion TorrentBought by Life Technologies$725MAug 2010
NuPatheListedUndisclosedAug 2010
Reliant PharmaceuticalsBought by GlaxoSmithKline$1.6BNov 2007
SyrrxBought by Takeda Pharmaceutical$270MFeb 2005
An exit counts when it came after the firm's first round in the company. From historical deal records.